Focused on next generation antibacterial therapeutics

Our Story
Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sciences, Pivotal bioVenture Partners, Sofinnova, TPG Biotechnology Partners and Eventide Gilead Fund, to advance our pipeline of breakthrough anti-infective products.

Our Approach
With our unique pathogen-targeted approach, we have developed a robust clinical and pre-clinical pipeline of potential first- and best-in-class medicines. This includes small-molecule programs to treat serious multidrug-resistant Gram-negative infections, including Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae, and a single dose oral therapy for susceptible and drug-resistant Neisseria gonorrhoeae.